Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.

Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M.

Clin Sci (Lond). 2019 Aug 27;133(16):1827-1844. doi: 10.1042/CS20190139. Print 2019 Aug 30.

PMID:
31409729
2.

Binding of an amphiphilic phthalocyanine to pre-formed liposomes confers light-triggered cargo release.

Macháček M, Carter KA, Kostelanský F, Miranda D, Seffouh A, Ortega J, Šimůnek T, Zimčík P, Lovell JF.

J Mater Chem B. 2018 Nov 28;6(44):7298-7305. doi: 10.1039/C8TB01602J. Epub 2018 Aug 22.

PMID:
30984399
3.

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.

Reimerová P, Jirkovská A, Piskáčková HB, Karabanovich G, Roh J, Šimůnek T, Štěrbová-Kovaříková P.

Sci Rep. 2019 Mar 14;9(1):4524. doi: 10.1038/s41598-019-40928-5.

4.

Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials.

Reimerová P, Stariat J, Bavlovič Piskáčková H, Jansová H, Roh J, Kalinowski DS, Macháček M, Šimůnek T, Richardson DR, Štěrbová-Kovaříková P.

Anal Bioanal Chem. 2019 Apr;411(11):2383-2394. doi: 10.1007/s00216-019-01681-w. Epub 2019 Mar 1.

PMID:
30820631
5.

2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress.

Jansová H, Kubeš J, Reimerová P, Štěrbová-Kovaříková P, Roh J, Šimůnek T.

Chem Res Toxicol. 2018 Nov 19;31(11):1151-1163. doi: 10.1021/acs.chemrestox.8b00165. Epub 2018 Nov 5.

PMID:
30395451
6.

Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities.

Hrušková K, Potůčková E, Opálka L, Hergeselová T, Hašková P, Kovaříková P, Šimůnek T, Vávrová K.

Chem Res Toxicol. 2018 Jun 18;31(6):435-446. doi: 10.1021/acs.chemrestox.7b00324. Epub 2018 May 23.

PMID:
29766723
7.

Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.

Jirkovský E, Jirkovská A, Bureš J, Chládek J, Lenčová O, Stariat J, Pokorná Z, Karabanovich G, Roh J, Brázdová P, Šimůnek T, Kovaříková P, Štěrba M.

J Pharmacol Exp Ther. 2018 Mar;364(3):433-446. doi: 10.1124/jpet.117.244848. Epub 2017 Dec 22.

PMID:
29273587
8.

Pharmacy Practice and Education in the Czech Republic.

Nachtigal P, Šimůnek T, Atkinson J.

Pharmacy (Basel). 2017 Oct 9;5(4). pii: E54. doi: 10.3390/pharmacy5040054.

9.

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.

Bures J, Jirkovska A, Sestak V, Jansova H, Karabanovich G, Roh J, Sterba M, Simunek T, Kovarikova P.

Toxicology. 2017 Dec 1;392:1-10. doi: 10.1016/j.tox.2017.09.012. Epub 2017 Sep 21.

PMID:
28941780
10.

Cardioprotective Potential of Iron Chelators and Prochelators.

Jansová H, Šimůnek T.

Curr Med Chem. 2019;26(2):288-301. doi: 10.2174/0929867324666170920155439. Review.

PMID:
28933303
11.

Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?

Lenčová-Popelová O, Jansová H, Jirkovský E, Bureš J, Jirkovská-Vávrová A, Mazurová Y, Reimerová P, Vostatková L, Adamcová M, Hroch M, Pokorná Z, Kovaříková P, Šimůnek T, Štěrba M.

Toxicology. 2016 Nov 30;372:52-63. doi: 10.1016/j.tox.2016.11.002. Epub 2016 Nov 2.

PMID:
27816693
12.

Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.

Hašková P, Jansová H, Bureš J, Macháček M, Jirkovská A, Franz KJ, Kovaříková P, Šimůnek T.

Toxicology. 2016 Sep 14;371:17-28. doi: 10.1016/j.tox.2016.10.004. Epub 2016 Oct 12.

13.

Tetra(3,4-pyrido)porphyrazines Caught in the Cationic Cage: Toward Nanomolar Active Photosensitizers.

Machacek M, Demuth J, Cermak P, Vavreckova M, Hruba L, Jedlickova A, Kubat P, Simunek T, Novakova V, Zimcik P.

J Med Chem. 2016 Oct 27;59(20):9443-9456. Epub 2016 Oct 5.

14.

Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.

Hrušková K, Potůčková E, Hergeselová T, Liptáková L, Hašková P, Mingas P, Kovaříková P, Šimůnek T, Vávrová K.

Eur J Med Chem. 2016 Sep 14;120:97-110. doi: 10.1016/j.ejmech.2016.05.015. Epub 2016 May 7.

PMID:
27187862
15.

Corrigendum to: "Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model" [Exp. Cell Res. 339 2 (2015) 174-186].

Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M.

Exp Cell Res. 2016 May 1;343(2):267. doi: 10.1016/j.yexcr.2016.02.007. Epub 2016 Apr 4. No abstract available.

PMID:
27155561
16.

Intravenous rutin in rat exacerbates isoprenaline-induced cardiotoxicity likely due to intracellular oxidative stress.

Filipský T, Říha M, Hašková P, Pilařová V, Nováková L, Semecký V, Vávrová J, Holečková M, Palicka V, Šimůnek T, Hrdina R, Mladěnka P.

Redox Rep. 2017 Mar;22(2):78-90. doi: 10.1080/13510002.2016.1159817. Epub 2016 Mar 21.

PMID:
27077454
17.

Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.

Jansová H, Bureš J, Macháček M, Hašková P, Jirkovská A, Roh J, Wang Q, Franz KJ, Kovaříková P, Šimůnek T.

Toxicology. 2016 Mar 28;350-352:15-24. doi: 10.1016/j.tox.2016.03.004. Epub 2016 Apr 1.

18.

Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury.

Říha M, Hašková P, Martin J, Filipský T, Váňová K, Vávrová J, Holečková M, Homola P, Vítek L, Palicka V, Šimůnek T, Mladěnka P.

Oxid Med Cell Longev. 2016;2016:5213532. doi: 10.1155/2016/5213532. Epub 2015 Dec 14.

19.

Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.

Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M.

J Mol Cell Cardiol. 2016 Feb;91:92-103. doi: 10.1016/j.yjmcc.2015.12.021. Epub 2015 Dec 23.

PMID:
26724189
20.

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.

Sestak V, Stariat J, Cermanova J, Potuckova E, Chladek J, Roh J, Bures J, Jansova H, Prusa P, Sterba M, Micuda S, Simunek T, Kalinowski DS, Richardson DR, Kovarikova P.

Oncotarget. 2015 Dec 15;6(40):42411-28. doi: 10.18632/oncotarget.6389.

21.

Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model.

Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M.

Exp Cell Res. 2015 Dec 10;339(2):174-86. doi: 10.1016/j.yexcr.2015.10.020. Epub 2015 Nov 5. Erratum in: Exp Cell Res. 2016 May 1;343 (2):267.

PMID:
26515555
22.

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.

Potůčková E, Roh J, Macháček M, Sahni S, Stariat J, Šesták V, Jansová H, Hašková P, Jirkovská A, Vávrová K, Kovaříková P, Kalinowski DS, Richardson DR, Šimůnek T.

PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015.

23.

Heteroatom-substituted tetra(3,4-pyrido)porphyrazines: a stride toward near-infrared-absorbing macrocycles.

Vachova L, Machacek M, Kučera R, Demuth J, Cermak P, Kopecky K, Miletin M, Jedlickova A, Simunek T, Novakova V, Zimcik P.

Org Biomol Chem. 2015 May 28;13(20):5608-12. doi: 10.1039/c5ob00651a. Epub 2015 Apr 17.

PMID:
25881971
24.

Far-red-absorbing cationic phthalocyanine photosensitizers: synthesis and evaluation of the photodynamic anticancer activity and the mode of cell death induction.

Machacek M, Cidlina A, Novakova V, Svec J, Rudolf E, Miletin M, Kučera R, Simunek T, Zimcik P.

J Med Chem. 2015 Feb 26;58(4):1736-49. doi: 10.1021/jm5014852. Epub 2015 Feb 4.

PMID:
25599409
25.

LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH).

Bureš J, Jansová H, Stariat J, Filipský T, Mladěnka P, Šimůnek T, Kučera R, Klimeš J, Wang Q, Franz KJ, Kovaříková P.

J Pharm Biomed Anal. 2015 Feb;105:55-63. doi: 10.1016/j.jpba.2014.11.044. Epub 2014 Dec 3.

26.

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.

Potůčková E, Hrušková K, Bureš J, Kovaříková P, Špirková IA, Pravdíková K, Kolbabová L, Hergeselová T, Hašková P, Jansová H, Macháček M, Jirkovská A, Richardson V, Lane DJ, Kalinowski DS, Richardson DR, Vávrová K, Šimůnek T.

PLoS One. 2014 Nov 13;9(11):e112059. doi: 10.1371/journal.pone.0112059. eCollection 2014.

27.

Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.

Serda M, Kalinowski DS, Rasko N, Potůčková E, Mrozek-Wilczkiewicz A, Musiol R, Małecki JG, Sajewicz M, Ratuszna A, Muchowicz A, Gołąb J, Simůnek T, Richardson DR, Polanski J.

PLoS One. 2014 Oct 16;9(10):e110291. doi: 10.1371/journal.pone.0110291. eCollection 2014.

28.

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

Jansová H, Macháček M, Wang Q, Hašková P, Jirkovská A, Potůčková E, Kielar F, Franz KJ, Simůnek T.

Free Radic Biol Med. 2014 Sep;74:210-21. doi: 10.1016/j.freeradbiomed.2014.06.019. Epub 2014 Jun 30.

29.

Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.

Lenčová-Popelová O, Jirkovský E, Mazurová Y, Lenčo J, Adamcová M, Šimůnek T, Geršl V, Štěrba M.

PLoS One. 2014 May 7;9(5):e96055. doi: 10.1371/journal.pone.0096055. eCollection 2014.

30.

Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.

Potuckova E, Jansova H, Machacek M, Vavrova A, Haskova P, Tichotova L, Richardson V, Kalinowski DS, Richardson DR, Simunek T.

PLoS One. 2014 Feb 20;9(2):e88754. doi: 10.1371/journal.pone.0088754. eCollection 2014.

31.

Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.

Stariat J, Suprunová V, Roh J, Šesták V, Eisner T, Filipský T, Mladěnka P, Nobilis M, Šimůnek T, Klimeš J, Kalinowski DS, Richardson DR, Kovaříková P.

Biomed Chromatogr. 2014 May;28(5):621-9. doi: 10.1002/bmc.3080. Epub 2013 Nov 20.

PMID:
24254882
32.

Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T.

PLoS One. 2013 Oct 7;8(10):e76676. doi: 10.1371/journal.pone.0076676. eCollection 2013.

33.

Water-soluble non-aggregating zinc phthalocyanine and in vitro studies for photodynamic therapy.

Makhseed S, Machacek M, Alfadly W, Tuhl A, Vinodh M, Simunek T, Novakova V, Kubat P, Rudolf E, Zimcik P.

Chem Commun (Camb). 2013 Dec 11;49(95):11149-51. doi: 10.1039/c3cc44609c.

PMID:
24040651
34.

Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.

Jirkovský E, Lenčová-Popelová O, Hroch M, Adamcová M, Mazurová Y, Vávrová J, Mičuda S, Šimůnek T, Geršl V, Štěrba M.

Toxicology. 2013 Sep 15;311(3):191-204. doi: 10.1016/j.tox.2013.06.012. Epub 2013 Jul 4.

PMID:
23831762
35.

Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium.

Kovarikova P, Pasakova-Vrbatova I, Vavrova A, Stariat J, Klimes J, Simunek T.

J Pharm Biomed Anal. 2013 Mar 25;76:243-51. doi: 10.1016/j.jpba.2012.12.024. Epub 2012 Dec 28.

PMID:
23339990
36.

Amino acid derivatives as transdermal permeation enhancers.

Janůšová B, Skolová B, Tükörová K, Wojnarová L, Simůnek T, Mladěnka P, Filipský T, Ríha M, Roh J, Palát K, Hrabálek A, Vávrová K.

J Control Release. 2013 Jan 28;165(2):91-100. doi: 10.1016/j.jconrel.2012.11.003. Epub 2012 Nov 12.

PMID:
23154194
37.

Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.

Jirkovsky E, Popelová O, Kriváková-Stanková P, Vávrová A, Hroch M, Hasková P, Brcáková-Dolezelová E, Micuda S, Adamcová M, Simůnek T, Cervinková Z, Gersl V, Sterba M.

J Pharmacol Exp Ther. 2012 Nov;343(2):468-78. doi: 10.1124/jpet.112.198358. Epub 2012 Aug 22.

PMID:
22915767
38.

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Stěrba M, Popelová O, Vávrová A, Jirkovský E, Kovaříková P, Geršl V, Simůnek T.

Antioxid Redox Signal. 2013 Mar 10;18(8):899-929. doi: 10.1089/ars.2012.4795. Epub 2012 Oct 12. Review.

39.

Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.

Macková E, Hrušková K, Bendová P, Vávrová A, Jansová H, Hašková P, Kovaříková P, Vávrová K, Simůnek T.

Chem Biol Interact. 2012 May 30;197(2-3):69-79. doi: 10.1016/j.cbi.2012.03.010. Epub 2012 Apr 11.

PMID:
22521999
40.

DNA topoisomerase IIβ: a player in regulation of gene expression and cell differentiation.

Vávrová A, Šimůnek T.

Int J Biochem Cell Biol. 2012 Jun;44(6):834-7. doi: 10.1016/j.biocel.2012.03.005. Epub 2012 Mar 24.

PMID:
22465709
41.

Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.

Hašková P, Koubková L, Vávrová A, Macková E, Hrušková K, Kovaříková P, Vávrová K, Simůnek T.

Toxicology. 2011 Nov 18;289(2-3):122-31. doi: 10.1016/j.tox.2011.08.006. Epub 2011 Aug 12.

PMID:
21864640
42.

Proteomic insights into chronic anthracycline cardiotoxicity.

Stěrba M, Popelová O, Lenčo J, Fučíková A, Brčáková E, Mazurová Y, Jirkovský E, Simůnek T, Adamcová M, Mičuda S, Stulík J, Geršl V.

J Mol Cell Cardiol. 2011 May;50(5):849-62. doi: 10.1016/j.yjmcc.2011.01.018. Epub 2011 Jan 31.

PMID:
21284945
43.

Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis.

Hruskova K, Kovarikova P, Bendova P, Haskova P, Mackova E, Stariat J, Vavrova A, Vavrova K, Simunek T.

Chem Res Toxicol. 2011 Mar 21;24(3):290-302. doi: 10.1021/tx100359t. Epub 2011 Jan 7.

PMID:
21214215
44.

Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.

Hašková P, Kovaříková P, Koubková L, Vávrová A, Macková E, Simůnek T.

Free Radic Biol Med. 2011 Feb 15;50(4):537-49. doi: 10.1016/j.freeradbiomed.2010.12.004. Epub 2010 Dec 13.

PMID:
21147217
45.

In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity.

Vávrová A, Popelová O, Stěrba M, Jirkovský E, Hašková P, Mertlíková-Kaiserová H, Geršl V, Simůnek T.

Arch Toxicol. 2011 May;85(5):525-35. doi: 10.1007/s00204-010-0615-8. Epub 2010 Nov 3.

PMID:
21046361
46.

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, Simunek T.

Chem Res Toxicol. 2010 Jun 21;23(6):1105-14. doi: 10.1021/tx100125t.

PMID:
20521781
47.

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

Popelová O, Sterba M, Hasková P, Simůnek T, Hroch M, Guncová I, Nachtigal P, Adamcová M, Gersl V, Mazurová Y.

Br J Cancer. 2009 Sep 1;101(5):792-802. doi: 10.1038/sj.bjc.6605192. Epub 2009 Jul 21.

48.

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.

Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V.

Pharmacol Rep. 2009 Jan-Feb;61(1):154-71. Review.

49.

The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity.

Mladĕnka P, Kalinowski DS, Haskova P, Bobrovová Z, Hrdina R, Simůnek T, Nachtigal P, Semecký V, Vávrová J, Holeckova M, Palicka V, Mazurová Y, Jansson PJ, Richardson DR.

Chem Res Toxicol. 2009 Jan;22(1):208-17.

PMID:
19172757
50.

Direct administration of rutin does not protect against catecholamine cardiotoxicity.

Mladenka P, Zatloukalová L, Simůnek T, Bobrovová Z, Semecký V, Nachtigal P, Hasková P, Macková E, Vávrová J, Holecková M, Palicka V, Hrdina R.

Toxicology. 2009 Jan 8;255(1-2):25-32. doi: 10.1016/j.tox.2008.09.027. Epub 2008 Oct 17.

PMID:
18992299

Supplemental Content

Loading ...
Support Center